Figure 3

BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists

Sheng Wang, Baohua Zhang and Douglas V Faller

  • The EMBO Journal (2004) 23, 2293 - 2303
  • doi:10.1038/sj.emboj.7600231

Published online: 13 May 2004

Back to article
Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Induction of association of prohibitin with Brg1/Brm by estrogen antagonists. (A) MCF7 cells were treated with 4HT or ICI182780 for the indicated time intervals. Cell extracts were immunoprecipitated (IP) by anti-cMyc (control), -Brg1, or -Brm antibodies, followed by immunoblot analysis (IB), using anti-prohibitin or -p38 (as control) antibodies. The reciprocal IP–immunoblot was performed using anti-cMyc or -prohibitin antibodies for the IP, and anti-Brg1, -Brm, or -p38 antibodies for the immunoblot. Increases in associations between prohibitin and Brg1/Brm were evident as early as 20 min after treatment. Immunoblotting with the anti-p38 antibody failed to detect any protein in the immunoprecipitates, indicating the specificity of the prohibitin–Brm/Brg1 associations. (B) The same cell extracts used in panel A were analyzed by immunoblot using anti-Brg1, -Brm, or -prohibitin antibodies. The results shown are representative of experiments that were repeated four times, which yielded identical results.

Back to article